Search

Author/Creator Bu, Xianwei

1. Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study. (April 2022)

Authors:
Coates, Laura C; Tillett, William; D'Agostino, Maria-Antonietta; Rahman, Proton; Behrens, Frank; McDearmon-Blondell, Erin L; Bu, Xianwei; Chen, Liang; Kapoor, Mudra; Conaghan, Philip G; Mease, Philip
Journal:
Lancet
Issue:
Volume 4:Number 4(2022)
Page Start:
e262
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Issue 11 (4th July 2022)

Authors:
van der Heijde, Désirée; Baraliakos, Xenofon; Sieper, Joachim; Deodhar, Atul; Inman, Robert D; Kameda, Hideto; Zeng, Xiaofeng; Sui, Yunxia; Bu, Xianwei; Pangan, Aileen L; Wung, Peter; Song, In-Ho
Journal:
Annals of the rheumatic diseases
Issue:
Volume 81:Issue 11(2022)
Page Start:
1515
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. Issue 1 (4th February 2022)

Authors:
Fleischmann, Roy; Mysler, Eduardo; Bessette, Louis; Peterfy, Charles G; Durez, Patrick; Tanaka, Yoshiya; Swierkot, Jerzy; Khan, Nasser; Bu, Xianwei; Li, Yihan; Song, In-Ho
Journal:
RMD open
Issue:
Volume 8:Issue 1(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗